DOCSLIB.ORG

Truesdail Laboratories, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Truesdail Laboratories, Inc DocuSign Envelope ID: D45F76C7-6019-45BE-A35A-B8879E2E6273 SERVICE CONTRACT AMENDMENT State Purchasing Bureau STATE OF NEBRASKA 1526 K Street, Suite 130 Lincoln, Nebraska 68508 PAGE ORDER DATE Telephone: (402) 471-6500 1 of 2 02/10/21 Fax: (402) 471-2089 BUSINESS UNIT BUYER 36100000 CONNIE HEINRICHS (AS) CONTRACT NUMBER VENDOR NUMBER: 4754100 80751 O4 VENDOR ADDRESS: ALS GROUP USA CORP PO BOX 975444 DALLAS TX 75397-5444 THE CONTRACT PERIOD IS: FEBRUARY 22, 2021 THROUGH FEBRUARY 21, 2022 THIS SERVICE CONTRACT HAS BEEN AMENDED PER THE FOLLOWING INFORMATION: THIS CONTRACT IS NOT AN EXCLUSIVE CONTRACT TO FURNISH THE SERVICES SHOWN BELOW, AND DOES NOT PRECLUDE THE PURCHASE OF SIMILAR SERVICES FROM OTHER SOURCES. THE STATE RESERVES THE RIGHT TO EXTEND THE PERIOD OF THIS CONTRACT BEYOND THE TERMINATION DATE WHEN MUTUALLY AGREEABLE TO THE VENDOR/CONTRACTOR AND THE STATE OF NEBRASKA. Original/Bid Document 5702 Z1 Contract to supply and deliver Analysis of Equine Urine and Blood Samples to the State of Nebraska as per the attached specifications for the period February 22, 2021 through February 21, 2022. Vendor Contact: Dr. Anthony J. Fontana Phone (Office): 714-730-6239 Ext. 190 Phone (Cellular): 509-432-9587 Fax: 714-730-6462 E-Mail: [email protected] This is the first renewal of the contract as amended. (02/10/21 ml) Amendment one as attached. (2/10/21 ml) Unit of Unit Extended Line Description Quantity Measure Price Price 1 PAIRED BLOOD AND URINE 1,500.0000 EA 96.0000 144,000.00 POST RACE ANALYSIS INITIAL PERIOD 2 SINGLE MATRIX BLOOD ONLY 360.0000 EA 58.0000 20,880.00 POST RACE ANALYSIS INITIAL PERIOD 3 SINGLE MATRIX BLOOD ONLY 15.0000 EA 58.0000 870.00 VETERINARIANS LIST INITIAL PERIOD 4 ANALYSIS OF CONFISCATED 15.0000 EA 40.0000 600.00 OR OTHERWISE ACQUIRED __________________________________ BUYER __________________________________ MATERIEL ADMINISTRATOR R43500|NISH0003|NISH0003 20150901 DocuSign Envelope ID: D45F76C7-6019-45BE-A35A-B8879E2E6273 SERVICE CONTRACT AMENDMENT State Purchasing Bureau STATE OF NEBRASKA 1526 K Street, Suite 130 Lincoln, Nebraska 68508 PAGE ORDER DATE Telephone: (402) 471-6500 2 of 2 02/10/21 Fax: (402) 471-2089 BUSINESS UNIT BUYER 36100000 CONNIE HEINRICHS (AS) CONTRACT NUMBER VENDOR NUMBER: 4754100 80751 O4 Unit of Unit Extended Line Description Quantity Measure Price Price SUBSTANCES LABELED INGREDIENTS INITIAL PERIOD 5 ANALYSIS OF CONFISCATED 15.0000 EA 40.0000 600.00 OR OTHERWISE ACQUIRED SUBSTANCES NO LABEL INGREDIENTS INITIAL PERIOD 6 PAIRED BLOOD AND URINE 500.0000 EA 96.0000 48,000.00 POST RACE ANALYSIS RENEWAL ONE 7 SINGLE MATRIX BLOOD ONLY 120.0000 EA 58.0000 6,960.00 POST RACE ANALYSIS RENEWAL ONE 8 SINGLE MATRIX BLOOD ONLY 5.0000 EA 58.0000 290.00 VETERINARIANS LIST RENEWAL ONE 9 ANALYSIS OF CONFISCATED 5.0000 EA 40.0000 200.00 OR OTHERWISE ACQUIRED SUBSTANCES LABELED INGREDIENTS RENEWAL ONE 10 ANALYSIS OF CONFISCATED 5.0000 EA 40.0000 200.00 OR OTHERWISE ACQUIRED SUBSTANCES NO LABEL INGREDIENTS RENEWAL ONE Total Order 222,600.00 ______________ BUYER INITIALS R43500|NISH0003|NISH0003 20150901 DocuSign Envelope ID: D45F76C7-6019-45BE-A35A-B8879E2E6273 AMENDMENT ONE Contract 80751 O4 Analysis of Equine Urine and Blood Samples for the State of Nebraska Between The State of Nebraska and ALS Group USA, Corp. This Amendment (the “Amendment”) is made by the State of Nebraska and ALS Group USA, Corp. parties to Contract 80751 O4, (the “Contract”), and upon mutual agreement and other valuable consideration, the parties agree to and hereby amend the Contract effective upon execution as follows: Amendment to reflect the Assignment of State of Nebraska Contract 80751 O4 dated August 14, 2018 from Truesdail Laboratories, Inc. to ALS Group USA, Corp. 1. WHEREAS, the State of Nebraska and Truesdail Laboratories, Inc. are parties to the State of Nebraska Contract 80751 O4. WHEREAS, the Contract requires written consent of the State before any assignment of the Contract and/or any rights and/or obligations under the contract may be made; WHEREAS, Truesdail Laboratories, Inc. has been sold to ALS Group USA, Corp.; WHEREAS, Truesdail Laboratories, Inc. wishes to assign its Contract, Nebraska Contract 80751 O4 and all of its rights and obligations under the State of Nebraska Contract 80751 O4 to ALS Group USA, Corp.; WHEREAS, ALS Group USA, Corp. assumes all the rights and obligations under the State of Nebraska Contract 80751 O4 from Truesdail Laboratories, Inc. and hereby agrees to fulfill all duties, responsibilities and obligations under said Contract; NOW, THEREFORE, on the basis of the representations made in the preamble above, which are hereby averred by Truesdail Laboratories, Inc. and ALS Group USA, Corp. each and together agrees to perform fully and faithfully all of the duties and obligations of which they have individually and together assumed herein pursuant to the State of Nebraska Contract 80751 O4 as amended, which is wholly made a part of this Assignment by this reference 2. To facilitate ALS Group USA, Corp. contractual obligations under Contract 80751 O4, Address Book Number, Contractor Name, Address and Contact Information in the original contract are hereby superseded and replaced with: Vendor Number: 4754100 Vendor Name and Address: ALS Group USA Corp. PO BOX 975444 Dallas, TX 75397-5444 Page 1 of 2 DocuSign Envelope ID: D45F76C7-6019-45BE-A35A-B8879E2E6273 Vendor Contact: Dr. Anthony J. Fontana Phone: 714-730-6239 Ext. 190 Cell: 509-432-9587 Fax: 714-730-6462 Email: [email protected] 3. Insurance Requirements section is hereby superseded and replaced by: III. CONTRACTOR DUTIES G. INSURANCE REQUIREMENTS 3. EVIDENCE OF COVERAGE The Contractor shall furnish the Buyer, with a certificate of insurance coverage complying with the above requirements prior to beginning work at: Department of Administrative Services Materiel Division – State Purchasing Bureau Attn: Connie Heinrichs, Buyer Email: [email protected] These certificates or the cover sheet shall reference the RFP number, and the certificates shall include the name of the company, policy numbers, effective dates, dates of expiration, and amounts and types of coverage afforded. If the State is damaged by the failure of the Contractor to maintain such insurance, then the Contractor shall be responsible for all reasonable costs properly attributable thereto. Reasonable notice of cancellation of any required insurance policy must be submitted to the contract manager as listed above when issued and a new coverage binder shall be submitted immediately to ensure no break in coverage. This Amendment and any attachments hereto will become part of the Contract. Except as set forth in this Amendment, the Contract is unaffected and shall continue in full force and effect in accordance with its terms. If there is conflict between this Amendment and the Contract or any earlier amendment, the terms of this Amendment will prevail. IN WITNESS WHEREOF, the parties have executed this Amendment as of the date of execution by both parties below. State of Nebraska Contractor: ALS Group USA, Corp. By: By: Randy Gates Name: Doug Carlson Name: Title: Materiel Administrator Title: Regional Manager 2/20/2021 2/19/2021 Date: Date: Page 2 of 2 DocuSign Envelope ID: D45F76C7-6019-45BE-A35A-B8879E2E6273 SERVICE CONTRACT AWARD State Purchasing Bureau STATE OF NEBRASKA 1526 K Street, Suite 130 Lincoln, Nebraska 68508 PAGE ORDER DATE Telephone: (402) 471-6500 1 of 2 02/10/21 Fax: (402) 471-2089 BUSINESS UNIT BUYER 36100000 CONNIE HEINRICHS (AS) CONTRACT NUMBER VENDOR NUMBER: 4754100 80751 O4 VENDOR ADDRESS: ALS GROUP USA CORP PO BOX 975444 DALLAS TX 75397-5444 AN AWARD HAS BEEN MADE TO THE VENDOR/CONTRACTOR NAMED ABOVE FOR THE SERVICES AS LISTED BELOW FOR THE PERIOD: FEBRUARY 22, 2021 THROUGH FEBRUARY 21, 2022 THIS CONTRACT IS NOT AN EXCLUSIVE CONTRACT TO FURNISH THE SERVICES SHOWN BELOW, AND DOES NOT PRECLUDE THE PURCHASE OF SIMILAR SERVICES FROM OTHER SOURCES. THE STATE RESERVES THE RIGHT TO EXTEND THE PERIOD OF THIS CONTRACT BEYOND THE TERMINATION DATE WHEN MUTUALLY AGREEABLE TO THE VENDOR/CONTRACTOR AND THE STATE OF NEBRASKA. Original/Bid Document 5702 Z1 Contract to supply and deliver Analysis of Equine Urine and Blood Samples to the State of Nebraska as per the attached specifications for the period February 22, 2021 through February 21, 2022. Vendor Contact: Dr. Anthony J. Fontana Phone (Office): 714-730-6239 Ext. 190 Phone (Cellular): 509-432-9587 Fax: 714-730-6462 E-Mail: [email protected] This is the first renewal of the contract as amended. (02/10/21 ml) Unit of Unit Extended Line Description Quantity Measure Price Price 1 PAIRED BLOOD AND URINE 1,500.0000 EA 96.0000 144,000.00 POST RACE ANALYSIS INITIAL PERIOD 2 SINGLE MATRIX BLOOD ONLY 360.0000 EA 58.0000 20,880.00 POST RACE ANALYSIS INITIAL PERIOD 3 SINGLE MATRIX BLOOD ONLY 15.0000 EA 58.0000 870.00 VETERINARIANS LIST INITIAL PERIOD 4 ANALYSIS OF CONFISCATED 15.0000 EA 40.0000 600.00 OR OTHERWISE ACQUIRED SUBSTANCES LABELED INGREDIENTS INITIAL PERIOD 5 ANALYSIS OF CONFISCATED 15.0000 EA 40.0000 600.00 OR OTHERWISE ACQUIRED __________________________________ BUYER __________________________________ MATERIEL ADMINISTRATOR R43500|NISK0002|NISK0002 20150901 DocuSign Envelope ID: D45F76C7-6019-45BE-A35A-B8879E2E6273 SERVICE CONTRACT AWARD State Purchasing Bureau STATE OF NEBRASKA 1526 K Street, Suite 130 Lincoln, Nebraska 68508 PAGE ORDER DATE Telephone: (402) 471-6500 2 of 2 02/10/21 Fax: (402) 471-2089 BUSINESS UNIT BUYER 36100000 CONNIE HEINRICHS (AS) CONTRACT NUMBER VENDOR
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • On the Approximation of the Laws of the Member States Relating to Cosmetic Products (76/768/EEC )
    27 . 9 . 76 Official Journal of the European Communities No L 262/169 COUNCIL DIRECTIVE of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products (76/768/EEC ) THE COUNCIL OF THE EUROPEAN COMMUNITIES, regards the composition, labelling and packaging of cosmetic products ; Having regard to the Treaty establishing the Euro­ pean Economic Community, and in particular Whereas this Directive relates only to cosmetic prod­ Article 100 thereof, ucts and not to pharmaceutical specialities and medicinal products ; whereas for this purpose it is necessary to define the scope of the Directive by Having regard to the proposal from the Commission, delimiting the field of cosmetics from that of phar­ maceuticals ; whereas this delimitation follows in particular from the detailed definition of cosmetic Having regard to the opinion of the European Parlia­ products, which refers both to their areas of appli­ ment ( 1 ), cation and to the purposes of their use; whereas this Directive is not applicable to the products that fall Having regard to the opinion of the Economic and under the definition of cosmetic product but are Social Committee (2 ), exclusively intended to protect from disease; whereas, moreover, it is advisable to specify that certain prod­ ucts come under this definition, whilst products Whereas the provisions laid down by law, regulation containing substances or preparations intended to be or administrative action in force in the Member ingested, inhaled, injected or implanted in the human States
    [Show full text]
  • 1 441 702 B1
    (19) TZZ__Z _T (11) EP 1 441 702 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/4045 (2006.01) A61P 25/20 (2006.01) 10.05.2017 Bulletin 2017/19 A61K 9/20 (2006.01) (21) Application number: 02760523.7 (86) International application number: PCT/IL2002/000662 (22) Date of filing: 12.08.2002 (87) International publication number: WO 2003/015690 (27.02.2003 Gazette 2003/09) (54) METHOD FOR TREATING PRIMARY INSOMNIA VERFAHREN ZUR BEHANDLUNG PRIMÄRER INSOMNIA METHODE DE TRAITEMENT DE L’INSOMNIE PRIMAIRE (84) Designated Contracting States: • ROTH T ET AL: "Consensus for the AT BE BG CH CY CZ DE DK EE ES FI FR GB GR pharmacological management of insomnia in th IE IT LI LU MC NL PT SE SK TR enew millennium", INTERNATIONAL JOURNAL Designated Extension States: OF CLINICAL PRACTICE, MEDICON LT LV RO SI INTERNATIONAL, ESHER, GB, vol. 55, no. 1, 1 January 2001 (2001-01-01), page 10PAGES, (30) Priority: 14.08.2001 IL 14490001 XP002990688, ISSN: 1368-5031 • PERLIS M L ET AL: "Psychophysiological (43) Date of publication of application: insomnia: the behavioural model and a 04.08.2004 Bulletin 2004/32 neurocognitive perspective", JOURNAL OF SLEEP RESEARCH, BLACKWELL SCIENTIFIC, (60) Divisional application: OXFORD, GB, vol. 6, 1 January 1997 (1997-01-01), 16172415.8 / 3 103 443 pages 179-188, XP002990686, ISSN: 0962-1105, DOI: DOI:10.1046/J.1365-2869.1997.00045.X (73) Proprietor: NEURIM PHARMACEUTICALS (1991) • SILVA J A C E ET AL: "Special report from a LIMITED symposium held by the WHO and the World Tel Aviv 69710 (IL) Federation of sleep research societies: an overview of insomnias and related disorders - (72) Inventor: ZISAPEL, Nava recognition, epidemiology and rational 69355 Tel Aviv (IL) management", SLEEP, ALLEN PRESS, LAWRENCE, KS,US, vol.
    [Show full text]
  • B COUNCIL DIRECTIVE of 27 July 1976 on the Approximation of the Laws of the Member States Relating to Cosmetic Products (76/768/EEC)
    1976L0768 — EN — 01.12.2010 — 028.001 — 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents ►B COUNCIL DIRECTIVE of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products (76/768/EEC) (OJ L 262, 27.9.1976, p. 169) Amended by: Official Journal No page date ►M1 Council Directive 79/661/EEC of 24 July 1979 L 192 35 31.7.1979 ►M2 Commission Directive 82/147/EEC of 11 February 1982 L 63 26 6.3.1982 ►M3 Council Directive 82/368/EEC of 17 May 1982 L 167 1 15.6.1982 ►M4 Commission Directive 83/191/EEC of 30 March 1983 L 109 25 26.4.1983 ►M5 Commission Directive 83/341/EEC of 29 June 1983 L 188 15 13.7.1983 ►M6 Commission Directive 83/496/EEC of 22 September 1983 L 275 20 8.10.1983 ►M7 Council Directive 83/574/EEC of 26 October 1983 L 332 38 28.11.1983 ►M8 Commission Directive 84/415/EEC of 18 July 1984 L 228 31 25.8.1984 ►M9 Commission Directive 85/391/EEC of 16 July 1985 L 224 40 22.8.1985 ►M10 Commission Directive 86/179/EEC of 28 February 1986 L 138 40 24.5.1986 ►M11 Commission Directive 86/199/EEC of 26 March 1986 L 149 38 3.6.1986 ►M12 Commission Directive 87/137/EEC of 2 February 1987 L 56 20 26.2.1987 ►M13 Commission Directive 88/233/EEC of 2 March 1988 L 105 11 26.4.1988 ►M14 Council Directive 88/667/EEC of 21 December 1988 L 382 46 31.12.1988 ►M15 Commission Directive 89/174/EEC of 21 February 1989 L 64 10 8.3.1989 ►M16 Council Directive 89/679/EEC of 21 December 1989 L 398 25 30.12.1989 ►M17 Commission Directive 90/121/EEC
    [Show full text]
  • Dopamine Transporter DAT; SLC6A3
    Dopamine Transporter DAT; SLC6A3 Dopamine transporter (DAT) is a plasma membrane protein that mediates the reuptake of extracellular dopamine (DA) and controls the spatiotemporal dynamics of dopaminergic neurotransmission. DATs play a key role in terminating dopaminergic signalling and in maintaining a releasable pool of dopamine. DATs help to modulate the concentration of extraneuronal dopamine by actively shuttling released transmitter molecules back across the plasma membrane into dopaminergic neurons, where they can be sequestered for later reuse or enzymatic catabolism. DAT is a principle target of various psychostimulant, nootropic, and antidepressant drugs, as well as certain drugs used recreationally, including the notoriously addictive stimulant cocaine. DAT ligands have traditionally been divided into two categories: cocaine-like inhibitors and amphetamine-like substrates. DAT is regulated by multiple signaling systems, such as PKC. www.MedChemExpress.com 1 Dopamine Transporter Inhibitors & Activators 13-Hydroxyisobakuchiol 5,7-Dimethoxyluteolin (Delta3,2-Hydroxylbakuchiol) Cat. No.: HY-N7506 Cat. No.: HY-111928 Hydroxyisobakuchiol (Delta3,2-Hydroxylbakuchiol), 5,7-Dimethoxyluteolin, a 5,7-dimethylluteolin an analog of Bakuchiol (HY-N0235) isolated from derivative, is a dopamine transporter (DAT) Psoralea corylifolia (L.), is a potent monoamine activator with an EC50 of 3.417 μM. transporter inhibitor. Purity: >98% Purity: 96.79% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 1 mg AHN 1-055 hydrochloride Amitifadine hydrochloride (3α-Bis-(4-fluorophenyl) Methoxytropane hydrochloride) Cat. No.: HY-101315 (DOV-21947 hydrochloride; EB-1010 hydrochloride) Cat. No.: HY-18332A AHN 1-055 hydrochloride is a dopamine uptake Amitifadine hydrochloride is a inhibitor, with an IC50 of 71 nM.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • United States Patent (10) Patent N0.: US 6,951,860 B2 Mehanna Et A1
    US006951860B2 (12) United States Patent (10) Patent N0.: US 6,951,860 B2 Mehanna et a1. (45) Date of Patent: Oct. 4, 2005 (54) CALCIUM CHANNEL BLOCKERS 5,132,106 A 7/1992 Tuloup et a1. ......... .. 514/223.5 5,134,139 A 7/1992 Kawai et a1. 514/211.07 Inventors: (Us); JinyungSI Mehanna, T_ Kim, Sudbury, Boston, MA 5,144,029 A 9/1992 AdamsWard et 618.1. a1. ............... .. 540/610 (Us) 5,198,433 A 3/1993 Palfreyman et a1. 514/217.11 5,276,026 A 1/1994 Barrrsh et a1. ....... .. 514/212.02 (73> Assignees Messeeheseees Cellege ef Phesmeey, 2:531:33 2 511333 81315152111111: 1:: iii/552:5 Bostons MA (Us) 5,360,809 A 11/1994 Axelsson 618.1. 514/338 _ _ _ _ _ 5,387,592 A 2/1995 Bradbury et a1. ......... .. 514/312 (*) Notlcel sublectto any dlsclalmer?heterm Ofthls 5,496,815 A 3/1996 OZeki et a1. .... .. 514/2242 patent is eXtended or adjusted under 35 5,514,693 A 5/1996 COZZl et a1. .... .. 514/341 U.S.C. 154(1)) by 183 days. 5,607,939 A 3/1997 Kato et a1. ................ .. 514/278 5,623,051 A 4/1997 Catterall et a1. .......... .. 530/324 (21) Appl. NO.Z 09/998,623 OTHER PUBLICATIONS (22) Flled: Oct‘ 31’ 2001 Gialdi et al., Abstract to CA 56:4664g.* (65) Prior Publication Data McMurry, John, Editor of Second Edition, Organic Chem istry, 1984, pp. 742—746.* Us 200301156551“ Aug- 22, 2002 Protiva, et al. of CZ 105,590 of CA59:10010f, Nov.
    [Show full text]
  • 2020 Equine Prohibited Substances List
    2020 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 25 November 2019, Lausanne, Switzerland 2020 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Final20october2009versionoflist 13 November 2009
    Prohibited Substances List This is not an official or current list of FEI Prohibited Substances. It is a working draft of a Prohibited Substance list that was already provided to you on 20 October 2009 and that will ultimately be presented to the FEI General Assemby in November 2009 alongside the Progressive List and the new Equine Anti-Doping and Controlled Medication Regulations(EADCM). Neither of the above-referenced Lists or the EADCM Regulations are in current usage, nor will they be unless voted into effect at the General assembly. The current list of FEI Prohibited Substances can be found at Annex II Vet Regs (11th edition) and remains in effect until otherwise notified. SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 38 Amineptine Tricyclic antidepressant 39 Aminoglutehthamide Aromatase inhibitor 1 Prohibited Substances List This is not an official or current list of FEI Prohibited Substances.
    [Show full text]
  • Transdermal Device Containing
    Europäisches Patentamt *EP000737066B1* (19) European Patent Office Office européen des brevets (11) EP 0 737 066 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: A61K 9/70, A61K 47/32 of the grant of the patent: 02.04.2003 Bulletin 2003/14 (86) International application number: PCT/US95/00022 (21) Application number: 95906742.2 (87) International publication number: (22) Date of filing: 09.01.1995 WO 95/018603 (13.07.1995 Gazette 1995/30) (54) TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER ALS LÖSLICHKEIT-STEIGERNDE GEBRAUCHTE POLYVINYLPYRROLIDON ENTHALTENDE TRANSDERMALE VORRICHTUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE CONTENANT DE LA POLYVINYLPYRROLIDONE EN TANT QU’AMPLIFICATEUR DE SOLUBILITE (84) Designated Contracting States: • SABLOTSKY, Steven AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL Miami, FL 33175 (US) PT SE (74) Representative: (30) Priority: 07.01.1994 US 178558 Werner, Hans-Karsten, Dr.Dipl.-Chem. et al Patentanwälte (43) Date of publication of application: Von Kreisler-Selting-Werner 16.10.1996 Bulletin 1996/42 Postfach 10 22 41 50462 Köln (DE) (73) Proprietor: NOVEN PHARMACEUTICALS, INC. Miami, FL 33186 (US) (56) References cited: EP-A- 0 201 828 EP-A- 0 272 045 (72) Inventors: EP-A- 0 343 807 EP-A- 0 416 842 • MIRANDA, Jesus EP-A- 0 529 123 WO-A-93/00058 Miami, FL 33186 (US) WO-A-93/08795 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • FEI Prohibited Substances List the 2011 List of FEI Prohibited Substances Will Come Into Effect on 4 April 2011
    Key to the changes for 2011: A substance highlighted in orange is a NEW addition to the Prohibited List A substance highlighted in blue has BEEN MOVED TO THIS CATEGORY on the Prohibited List A substance highlighted in green has been previously listed but is now REMOVED from the List FEI Prohibited Substances List The 2011 List of FEI Prohibited Substances will come into effect on 4 April 2011. The FEI Prohibited Substances List will be reviewed for suitability and any changes introduced on an annual basis. Please check http://www.fei.org for the latest version of this List. SUBSTANCE ACTIVITY BANNED SUBSTANCES 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin Non-steroidal anti-inflammatory drug 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/antipyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic 8 Acetophenazine Antipsychotic 9 Acetophenetidin (Phenacetin) Analgesic 10 Acetylmorphine Narcotic 11 Adinazolam Anxiolytic 12 Adiphenine Antispasmodic 13 Adrafinil Stimulant 14 Adrenaline Stimulant 15 Adrenochrome Haemostatic 16 Aformoterol Bronchodilator 17 Alclofenac Non-steroidal anti-inflammatory drug 18 Alcuronium Muscle relaxant 19 Aldosterone Hormone 20 Alfentanil Narcotic 21 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 22 Almotriptan 5-hydroxatryptamine agonist (antimigraine) 23 Alphadolone acetate Neurosteroid 24 Alphaprodine Opiod analgesic 25 Alpidem Anxiolytic 26 Alprazolam Anxiolytic 27 Alprenolol Beta blocker 28 Althesin IV anaesthetic 29 Althiazide Diuretic
    [Show full text]